1. Introduction of the Company<\/b><\/p>\n
Dr Reddy\u2019s Laboratories Ltd. is one of India\u2019s leading multinational pharmaceutical companies, established in 1984<\/b>. The company operates across active pharmaceutical ingredients (APIs), generic formulations, biosimilars, and proprietary products. It has a strong presence in domestic as well as international markets, including the United States, Europe, and emerging economies.<\/p>\n
Being a large-cap pharmaceutical stock, Dr Reddy\u2019s share price is influenced not only by overall market movements but also by industry-specific factors<\/b> such as regulatory approvals, drug pipelines, patent expiries, and global healthcare demand. This study evaluates how the returns of Dr Reddy\u2019s Laboratories relate to movements in the broader market index, NIFTY 50<\/b>.<\/p>\n 2. Objective<\/b><\/p>\n The primary objective of this study is to analyze the relationship between Dr Reddy\u2019s Laboratories\u2019 returns and the NIFTY 50 index<\/b> using historical data.<\/p>\n Specific objectives include:<\/p>\n 3. Literature Review<\/b><\/p>\n This study is based on the Capital Asset Pricing Model (CAPM)<\/b>, which explains the relationship between expected return and market risk.<\/p>\n Systematic Risk (Beta)<\/b><\/p>\n Beta measures the sensitivity of a stock\u2019s returns to changes in the overall market:<\/p>\n Unsystematic Risk<\/b><\/p>\n Unsystematic risk arises from firm-specific factors such as:<\/p>\n This risk is unique to the company and is not explained by market movements.<\/p>\n Regression Model<\/b><\/p>\n The CAPM regression equation used in this study is:<\/p>\n Ri\u200b=\u03b1+\u03b2Rm\u200b+\u03f5<\/span><\/b><\/p>\n Where:<\/p>\n \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><\/span><\/span>Ri\u200b = Return of Dr Reddy\u2019s Laboratories.<\/p>\n \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><\/span><\/span>Rm\u200b = Return of NIFTY 50.<\/p>\n \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><\/span><\/span>\u03b1 = Alpha (excess return).<\/p>\n \u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><\/span><\/span>\u03f5<\/span> = Error term<\/p>\n 4. Data Collection<\/b><\/p>\n The data used in this study was taken directly from the Excel file (Merged Data.xlsx)<\/b>.<\/p>\n Data Details<\/b><\/p>\n Variables Used<\/b><\/p>\n The weekly returns for both the stock and the index were already computed in the dataset and used directly for regression analysis.<\/p>\n 5. Data Analysis<\/b><\/p>\n A linear regression analysis<\/b> was performed using weekly returns of Dr Reddy\u2019s Laboratories against weekly returns of NIFTY 50.<\/p>\n Regression Results (from Excel-based analysis)<\/b><\/p>\n Interpretation<\/b><\/p>\n Regression Equation<\/b><\/p>\n DR\u00a0Reddy\u2019s\u00a0Return=\u22120.07\u22120.18(NIFTY\u00a050\u00a0Return)<\/span><\/b><\/p>\n 6. Conclusion<\/b><\/p>\n The study concludes that Dr Reddy\u2019s Laboratories exhibits very low and negative systematic risk<\/b> during the period from December 2024 to November 2025. The stock does not move closely with the broader market and shows defensive characteristics<\/b>.<\/p>\n Key Findings<\/b><\/p>\n Investor Implications<\/b><\/p>\n 7. References<\/b><\/p>\n 1. Introduction of the Company Dr Reddy\u2019s Laboratories Ltd. is one of India\u2019s leading multinational pharmaceutical companies, established in 1984. The company operates across active pharmaceutical ingredients (APIs), generic formulations, biosimilars, and proprietary products. It has a strong presence in domestic as well as international markets, including the United States, Europe, and emerging economies. Being… Continue reading A Study on the Relationship between NIFTY 50 and DR Reddy\u2019s Laboratories Ltd.<\/span><\/a><\/p>\n","protected":false},"author":140007,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-23310","post","type-post","status-publish","format-standard","hentry","category-uncategorized","entry"],"_links":{"self":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/23310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/users\/140007"}],"replies":[{"embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23310"}],"version-history":[{"count":1,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/23310\/revisions"}],"predecessor-version":[{"id":23311,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/23310\/revisions\/23311"}],"wp:attachment":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23310"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/div>\n\n
<\/div>\n\n
\n
<\/div>\n\n
\n
<\/div>\n\n
\n
The negative beta indicates a weak inverse relationship<\/b> between Dr Reddy\u2019s stock returns and NIFTY 50 returns. For every 1% change in the NIFTY 50, Dr Reddy\u2019s returns move by approximately \u20130.18%<\/b>. This suggests that the stock has low market sensitivity<\/b>.<\/li>\n
The negative alpha implies that the stock generated slightly negative excess returns<\/b> when the market return was zero during the study period.<\/li>\n
Only 1% of the variation<\/b> in Dr Reddy\u2019s returns is explained by movements in the NIFTY 50, indicating that most of the price movement is driven by company-specific and industry-specific factors<\/b>.<\/li>\n<\/ul>\n
<\/div>\n\n
\n
<\/div>\n\n